EGFR and cancer: Importantly, the IL-1 blockade had no effect on the anti-cancer efficacy of anti-EGFR mAb, but increased IL-1α expression and successfully induced a T cell-dependent anti-cancer immune response and reduced the immune suppressive cell action [570].